OWP
OBIO icon

Old Well Partners’s Orchestra BioMed OBIO Stock Holding History

Old Well Partners’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,300
Closed -$183K – 50
2020
Q4 		$183K Hold
14,300
– – 0.09% 38
2020
Q3 		$157K Buy
+14,300
New +$161K 0.15% 26

Other funds holding OBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AC
Amitell Capital Singapore $62.4M AUM 75.98% 1-Year Est. Return

Old Well Partners's OBIO Position: Q1 2021 in Review

Old Well Partners sold out of Orchestra BioMed (OBIO) in Q1 2021, closing a stake of 14,300 shares — an estimated $183K sold.

Old Well Partners first reported a position in OBIO in Q3 2020 and held it in 2 quarters. The position peaked at $183K in Q4 2020. 46 funds tracked by Wall St. Rank hold OBIO as of Q1 2021.

  • Old Well Partners reported no remaining Orchestra BioMed position as of Q1 2021 after selling out during the quarter.
  • Old Well Partners sold 14,300 Orchestra BioMed shares in Q1 2021, an estimated $183K.
  • Old Well Partners first reported a position in Orchestra BioMed in Q3 2020 and held it in 2 quarters.
  • Old Well Partners's Orchestra BioMed position peaked at $183K in Q4 2020.
  • 46 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2021.

Based on Old Well Partners's 13F filing for Q1 2021, filed 17 May 2021.